CD24和Siglec-10在上皮性卵巢癌组织中的表达及意义

陈姝; 张競; 李燕华

doi:10.16766/j.cnki.issn.1674-4152.001828

CD24和Siglec-10在上皮性卵巢癌组织中的表达及意义

doi: 10.16766/j.cnki.issn.1674-4152.001828

蚌埠医学院第一附属医院妇瘤科，安徽蚌埠 233004

基金项目:

安徽省教育厅高校自然科学研究重点项目 KJ2019A0384

详细信息

通讯作者:
李燕华, E-mail: bblyh1964@126.com

中图分类号: R737.31 R730
计量
- 文章访问数: 450
- HTML全文浏览量: 265
- PDF下载量: 8
- 被引次数: 0
出版历程
- 收稿日期: 2020-10-15
- 网络出版日期: 2022-02-19

The expression and significance of CD24 and Siglec-10 in epithelial ovarian cancer

Department of Gynecologic Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

摘要

摘要: 目的分析CD24、Siglec-10在不同卵巢组织中的表达, 探讨两者在上皮性卵巢癌组织中的表达及意义。方法通过免疫组织化学(SP)法检测CD24、Siglec-10的表达情况, 分析两者在不同卵巢组织中的表达情况及特点, 探讨CD24、Siglec-10与上皮性卵巢癌不同病理参数之间的关系以及两参数之间的关系, 并结合随访结果探索其与上皮性卵巢癌的发生发展、侵袭转移及复发的关系。结果 CD24、Siglec-10在正常卵巢组织中不表达, 其表达水平随卵巢肿瘤的良性、交界性、恶性变化而增加, 各组间差异具有统计学意义(均P＜0.05);CD24、Siglec-10的表达水平与FIGO分期、淋巴结转移、大网膜转移、盆腹腔种植灶、复发密切相关(均P＜0.05);CD24和Siglec-10在上皮性卵巢癌中的高表达水平具有明显相关性(r=0.500, P＜0.001)。结论 CD24和Siglec-10具有协同作用, 能够共同促进卵巢肿瘤的发生发展、侵袭、转移, 并且与复发密切相关; CD24-Siglec-10有望成为新的免疫检测点, 为上皮性卵巢癌在免疫治疗方面提供更多的可能。
- 卵巢肿瘤 /
- CD24 /
- 唾液酸结合免疫球蛋白型凝集素10 /
- 免疫组织化学 /
- 复发
Abstract: Objective To analyze the expression of CD24 and Siglec-10 in different ovarian tissues, and to explore their expression and significance in epithelial ovarian cancer. Methods The expression of CD24 and Siglec-10 were detected by immunohistochemistry (SP), their expression and characteristics in different ovarian tissues were analyzed. The relationship between CD24, Siglec-10 and different pathological parameters of epithelial ovarian cancer and the relationship between the two parameters were investigated, and the relationship between CD24, Siglec-10 and the occurrence, development, invasion, metastasis and recurrence of epithelial ovarian cancer were explored. Results CD24 and Siglec-10 were not expressed in normal ovarian tissues, and their expression levels increased with the benign, borderline, and malignant changes of ovarian tumors, the difference between the groups was statistically significant (P < 0.05). The expression level of CD24 and Siglec-10 was closely related to FIGO staging, lymph node metastasis, omental metastasis, pelvic and abdominal implantation, and recurrence, the difference was statistically significant (P < 0.05). The highly expression level of CD24 and Siglec-10 had a significant correlation in epithelial ovarian cancer (r=0.500, P < 0.001). Conclusion CD24 and Siglec-10 have a synergistic effect, which can jointly promote the occurrence and development, invasion, metastasis and recurrence of tumors. CD24-Siglec-10 is expected to become a new immune detection point, providing more possibilities for the immunotherapy of epithelial ovarian cancer.
- Ovarian tumors /
- CD24 /
- Siglec-10 /
- Immunohistochemistry /
- Recurrence

HTML全文

表 1 CD24、Siglec-10在不同卵巢组织中的表达比较(例)

组别	例数	组织中CD24的表达			组织中Siglec-10的表达
组别	例数	-	+~+++	阳性率(%)	-	+~+++	阳性率(%)
卵巢良性肿瘤	26	20	6	23.1	20	6	23.1
卵巢交界性肿瘤	24	11	13	54.2	8	16	66.7
卵巢上皮性癌	71	8	63	88.7	7	64	90.1
χ²值		40.093			41.916
P值		＜0.001			＜0.001

下载: 导出CSV

表 2 CD24、Siglec-10与上皮性卵巢癌不同临床病理参数之间的关系(例)

临床病理参数	例数	组织中CD24的表达				组织中Siglec-10的表达
临床病理参数	例数	高表达	低表达	χ²值	P值	高表达	低表达	χ²值	P值
组织学类型					0.999^a				0.341^a
浆液性	61	43	18			45	16
黏液性	6	4	2			3	3
组织学分级					0.113^a				0.124^a
G1级	9	4	5			4	5
G2、G3级	62	46	16			45	17
FIGO分期					< 0.001^a			15.190	< 0.001
Ⅰ、Ⅱ期	25	8	17			10	15
Ⅲ、Ⅳ期	46	42	4			39	7
淋巴结转移					0.042^a				0.030^a
有	8	7	1			7	1
无	17	7	10			6	11
大网膜转移					< 0.001^a			6.878	0.009
有	39	36	3			32	7
无	32	14	18			17	15
腹水					0.361^a			1.085	0.298
有	54	36	18			39	15
无	17	14	3			10	7
盆腹腔种植灶				14.040	＜0.001			17.001	＜0.001
有	52	43	9			43	9
无	19	7	12			6	13
注：^a为采用Fisher精确检验。

下载: 导出CSV

表 3 CD24与Siglec-10表达的相关性(例)

CD24	Siglec-10		r值	P值
CD24	高表达	低表达	r值	P值
高表达	42	8	0.500	＜0.001
低表达	7	14

下载: 导出CSV

表 4 CD24、Siglec-10的表达与复发的关系(例)

复发情况	例数	CD24表达				Siglec-10表达
复发情况	例数	高表达	低表达	高表达率(%)	P值	高表达	低表达	高表达率(%)	P值
有	43	34	9	79.1	0.048^a	32	11	74.4	0.045^a
无	9	4	5	44.4		3	6	33.3
注：^a为采用Fisher精确检验。

下载: 导出CSV

参考文献(22)

[1]	NAKAMURA K, TERAI Y, TANABE A, et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways[J]. Oncol Rep, 2017, 37(6): 3189-3200. doi: 10.3892/or.2017.5583
[2]	EISENHAUER E A. Real-world evidence in the treatment of ovarian cancer[J]. Ann Oncol, 2017, 28(suppl 8): 1161-1165. http://www.ncbi.nlm.nih.gov/pubmed/28574933
[3]	PIGNATA S, CECERE C S, BOIS A D, et al. Treatment of recurrent ovarian cancer[J]. Ann Oncol, 2017, 28(suppl 8): 51-56.
[4]	MORGAN R J, ARMSTRONG D K, ALVAREZ R D, et al. Ovarian cancer, Version 1.2016, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2016, 14(9): 1134-1163. doi: 10.6004/jnccn.2016.0122
[5]	TORRE L A, TRABERT B, DESANTIS C E, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(4): 284-296. doi: 10.3322/caac.21456
[6]	HENDERSON J T, WEBBER E M, SAWAYA G F. Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force[J]. JAMA, 2018, 319(6): 595-606. doi: 10.1001/jama.2017.21421
[7]	DUEX J E, OWENS C, CHAUCA-DIAZ A, et al. Nuclear CD24 drives tumor growth and is predictive of poor patient prognosis[J]. Cancer Res, 2017, 77(18): 4858-4867. doi: 10.1158/0008-5472.CAN-17-0367
[8]	BARKAL A A, BREWER R E, MARKOVIC M, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy[J]. Nature, 2019, 572(7769): 392-396. doi: 10.1038/s41586-019-1456-0
[9]	PEI Z, ZHU G, HUO X, et al. CD24 promotes the proliferation and inhibits the apoptosis of cervical cancer cells in vitro[J]. Oncol Rep, 2016, 35(3): 1593-1601. doi: 10.3892/or.2015.4521
[10]	ROSTOKER R, ABELSON S, GENKIN I, et al. CD24(+) cells fuel rapid tumor growth and display high metastatic capacity[J]. Breast Cancer Res, 2015, 17(1): 78. doi: 10.1186/s13058-015-0589-9
[11]	EYVAZI S, KAZEMI B, DASTMALCHI S, et al. Involvement of CD24 in multiple cancer related pathways makes it an interesting new target for cancer therapy[J]. Curr Cancer Drug Targets, 2018, 18(4): 328-336. doi: 10.2174/1570163814666170818125036
[12]	DENG X, APPLE S, ZHAO H, et al. CD24 Expression and differential resistance to chemotherapy in triple -negative breast cancer[J]. Oncotarget, 2017, 8(24): 38294-38308. doi: 10.18632/oncotarget.16203
[13]	KWON M J, HAN J, SEO J H, et al. CD24 Overexpression is associated with poor prognosis in luminal a and triple-negative breast cancer[J]. PLoS One, 2015, 10(10): e0139112. doi: 10.1371/journal.pone.0139112
[14]	YANG X R, XU Y, YU B, et al. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery[J]. Clin Cancer Res, 2009, 15(17): 5518-5527. doi: 10.1158/1078-0432.CCR-09-0151
[15]	KRISTIANSEN G, SCHLVNS K, YONGWEI Y, et al. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients[J]. Br J Cancer, 2003, 88(2): 231-236. doi: 10.1038/sj.bjc.6600702
[16]	LIU C, ZHENG S, SHEN H, et al. Clinical significance of CD24 as a predictor of bladder cancer recurrence[J]. Oncol Lett, 2013, 6(1): 96-100. doi: 10.3892/ol.2013.1357
[17]	OVERDEVEST J B, KNUBEL K H, DUEX J E, et al. CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated[J]. Proc Natl Acad Sci U S A, 2012, 109(51): 3588-3596. doi: 10.1073/pnas.1113960109
[18]	LI Y, ZHOU J, ZHUO Q, et al. Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression[J]. Cancer Manag Res, 2019, 11(4): 7123-7134. http://www.ncbi.nlm.nih.gov/pubmed/31534365
[19]	ABRAM C L, LOWELL C A. Shp1 function in myeloid cells[J]. J Leukoc Biol, 2017, 102(3): 657-675. doi: 10.1189/jlb.2MR0317-105R
[20]	KLEMBA A, PURZYCKA-OLEWIECKA J K, WCISO G, et al. Surface markers of cancer stem-like cells of ovarian cancer and their clinical relevance[J]. Contemp Oncol(Pozn), 2018, 22(1A): 48-55. http://www.termedia.pl/Journal/-77/pdf-32001-10?filename=Surface%20markers%20of%20cancer.pdf
[21]	NAKAMURA K, TERAI Y, TANABE A, et al. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways[J]. Oncol Rep, 2017, 37(6): 3189-3200. doi: 10.3892/or.2017.5583
[22]	刘恒炜, 吕立群. 基于Oncomine数据库荟萃分析CD24在卵巢癌中的表达和临床意义[J]. 国际妇产科学杂志, 2019, 46(5): 580-584. doi: 10.3969/j.issn.1674-1870.2019.05.025